Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 December 2024 | Story Edzani Nephalela | Photo Supplied
Stefanus Scheepers
The recently dual-capped Stefanus Scheepers, Senior Admin Assistant Officer in the UFS Faculty of Education, says his success lies in mastering the art of balance.

Completing a master’s degree in record time is a remarkable achievement, but for Stefanus Scheepers, Senior Admin Assistant Officer at the University of the Free State Faculty of Education, it marked the beginning of an even more extraordinary academic journey. In a feat few could match, he earned two master’s degrees in just 20 months.

Scheepers’ first degree, a Master of Education specialising in Higher Education Studies, was conferred by the University of the Free State (UFS) on 9 December 2024. His thesis, ‘Effective Pedagogical Practices Teaching Assistants Use in Hybrid Teaching Modes: A Community of Inquiry Approach’, explored innovative teaching strategies in hybrid learning environments.

The second degree, a Master of Science by Research in Sustainable African Futures, was conferred through the Wits-Edinburgh Sustainable African Futures (WESAF) Doctoral Programme. His thesis, ‘Investigating the Perception, Adoption, and Utilization of Generative Artificial Intelligence in South African Higher Education Institutions’, examined the impact of generative artificial intelligence (GAI) on sustainable education in South Africa.

“My experience presenting workshops on GAI tools and its misuse by students sparked my research interest,” he explained. The resulting mini-dissertation shed light on the critical need for sustainable education practices in an era increasingly influenced by AI. This theme will continue as Scheepers embarks on a PhD at Wits University in 2025, exploring how to balance GAI’s benefits and risks in education.

Initially, Scheepers embarked on a part-time master’s degree in 2023 at the UFS while working full-time. “I hadn’t planned to complete two degrees,” he said, “but my supervisor’s encouragement and excellent guidance made completing the degree within a year seem possible.” Midway through, however, a nomination from the Dean and Vice-Dean of the Faculty of Education changed everything. The WESAF Doctoral Programme offered an opportunity that was too valuable to pass up, even though it added another degree to his demanding schedule.

“At first I was very hesitant, but my supervisor said that I would regret not taking it”, he said with a smile.

Time management does the trick

Balancing the demands of studying for two master’s degrees was no small feat. Scheepers chose to embrace meticulous time management, creating a schedule that integrated study and rest.

“Time management is not just about making a plan but sticking to it,” he emphasised. This structured approach allowed him to maximise productivity without burnout. “I must admit, working at night in your office did feel strange at first, but tranquil after a while.” Weekends included much-needed downtime, which helped him maintain resilience throughout.

Reflecting on this intense period, Scheepers attributes his success to cumulative skills gained over the years. “Every skill learnt in prior degrees was put to the test. The journey wasn’t easy, but intentionally applying these skills made the challenge rewarding.”

After nearly six years at higher education institutions – Scheepers’ career ambition is to transition into a lecturer role, with the hope of passing on his research and hands-on experience to a new generation of students.

When asked what he would share with prospective students at the UFS, Scheepers said, “The path to success isn’t always straightforward. I’ve experienced setbacks, even dropping out twice before finding my footing. But each challenge taught me resilience and determination. To all students: Keep going, even when the journey feels daunting. Every obstacle you overcome is a step closer to your goals. Remember, success is not about avoiding failure but learning and growing stronger with each experience. Stay focused, believe in yourself, and trust the process – you can do much more than you may realise.”

This remarkable dual graduation is not only a rare achievement in academia but also highlights Scheepers’ exceptional time management, strategic planning, and unwavering commitment to advancing the fields of education and sustainable futures.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept